According to the article, "Schering's case reveals the ugly reality of the pharma business. Lacking genuinely new medicines or definitive proof that their costly, patented drugs work better than cheap ones, producers are forced to turn minor marketing advantages into billion-dollar oppotunities. Hassan's great at this."
Schering had a problem with trial data from a study of arteries in 2006; last year an outside investigator called it "a mess."
Tell it to the cholesterol skeptics.
When Hassan was hired, the problems were so bad he brought in a compliance officer, who hired 100 (count 'em) compliance managers. No wonder they want their patent monopolies.